Blog
RSS FeedPosted by Michael Wonder on 04 Feb 2018
Tagrisso (osimertinib) receives full Health Canada approval for targeted treatment of non-small-cell lung cancer
31 January 2018 - Approval based on Phase III AURA3 trial that demonstrated significant improvement in progression-free survival with Tagrisso compared ...
Posted by Michael Wonder on 02 Feb 2018
New treatment option for adults with ADHD: Foquest (methylphenidate controlled release capsules) now available in Canada
1 February 2018 - First and only methylphenidate product approved in Canada with a 16-hour duration of action. ...
Posted by Michael Wonder on 24 Jan 2018
Lartruvo (olaratumab) approved in Canada for the treatment of advanced soft tissue sarcoma in adults
24 January 2018 - Health Canada has issued a Notice of Compliance with Conditions for Lartruvo (olaratumab). ...
Posted by Michael Wonder on 10 Jan 2018
Ozempic approved in Canada for the treatment of adults with type 2 diabetes
9 January 2018 - Ozempic demonstrated clinically meaningful improvements in blood sugar and body weight vs comparators. ...
Posted by Michael Wonder on 10 Jan 2018
Ipsen Biopharmaceuticals Canada announces Health Canada approval of Dysport Therapeutic (abobotulinumtoxinA) for the treatment of lower limb spasticity in children aged two and older
9 January 2018 - Ipsen Biopharmaceuticals Canada today announced that Health Canada has approved Dysport Therapeutic (abobotulinumtoxinA) for the treatment ...
Posted by Michael Wonder on 04 Jan 2018
Xiidra (lifitegrast ophthalmic solution 5%) approved by Health Canada to treat the signs and symptoms of dry eye disease
3 January 2018 - Canada approval represents Shire’s first international market authorisation for Xiidra outside of the United States. ...
Posted by Michael Wonder on 13 Dec 2017
New concentrated insulin approved and available for Canadian patients
12 December 2017 - Entuzity KwikPen is five times more concentrated than the current option. ...
Posted by Michael Wonder on 05 Dec 2017
Health Canada approves Rydapt (midostaurin), first targeted therapy for common form of acute myeloid leukaemia
5 December 2017 - Targeted therapy treats most common gene mutation (FLT3) found in more than one third of AML patients. ...
Posted by Michael Wonder on 05 Dec 2017
Health Canada approves Dupixent, the first targeted treatment for adults with moderate-to-severe atopic dermatitis
4 December 2017 - Patients saw a clinically significant improvement in the condition of their skin and reduction in itch within ...
Posted by Michael Wonder on 05 Dec 2017
EMD Serono receives Health Canada Notice of Compliance for Mavenclad (cladribine tablets) for patients living with relapsing-remitting multiple sclerosis
4 December 2017 - EMD Serono Canada announced today that Health Canada has approved Mavenclad (cladribine tablets) as monotherapy for the ...
Posted by Michael Wonder on 28 Nov 2017
Sobi receives approval from Health Canada for Orfadin oral suspension for the treatment of HT-1
27 November 2017 - Swedish Orphan Biovitrum (Sobi) has received approval from Health Canada for an oral suspension formulation of Orfadin ...
Posted by Michael Wonder on 22 Nov 2017
Health Canada approves Victoza as the first and only GLP-1 receptor agonist to reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease
21 November 2017 - Cardiovascular disease is the leading cause of death for people with T2D, who are at a 2 ...
Posted by Michael Wonder on 16 Nov 2017
Janssen announces Health Canada approval of Tremfya (guselkumab) for the treatment of adult moderate to severe plaque psoriasis
15 November 2017 - Tremfya is the first approved biologic that selectively blocks interleukin-23. ...
Posted by Michael Wonder on 14 Nov 2017
Xalkori approved by Health Canada for the treatment of patients with ROS1-positive locally advanced or metastatic non-small-cell lung cancer
14 November 2017 - First Health Canada approved treatment for Canadians with ROS1 non-small-cell lung cancer. ...
Posted by Michael Wonder on 07 Nov 2017
Health Canada approves Imfinzi (durvalumab) for previously treated patients with advanced bladder cancer
6 November 2017 - Approval granted based on promising tumour response rate and duration of response. ...